Clinical Trials Browser

NETWORK × Hodgkin Disease × pembrolizumab × Clear all

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease